Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 in type 2 diabetes mellitus
CTR20231357Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of olatorepatide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started May 2023; status: completed.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20231357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231357.